Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin-beta receptor signaling.

  1. Xing Feng
  2. Ruifeng Sun
  3. Moonyoung Lee
  4. Xinyue Chen
  5. Shangqin Guo
  6. Huimin Geng
  7. Marcus Müschen
  8. Jungmin Choi  Is a corresponding author
  9. Joao Pedro Pereira  Is a corresponding author
  1. Yale University, United States
  2. Korea University, Republic of Korea
  3. University of California, San Francisco, United States

Abstract

Acute lymphoblastic and myeloblastic leukemias (ALL and AML) have been known to modify the bone marrow microenvironment and disrupt non-malignant hematopoiesis. However, the molecular mechanisms driving these alterations remain poorly defined. Using mouse models of ALL and AML, here we show that leukemic cells turn-off lymphopoiesis and erythropoiesis shortly after colonizing the bone marrow. ALL and AML cells express lymphotoxin-a1b2 and activate LTbR signaling in mesenchymal stem cells (MSCs), which turns off IL7 production and prevents non-malignant lymphopoiesis. We show that the DNA damage response pathway and CXCR4 signaling promote lymphotoxin-a1b2 expression in leukemic cells. Genetic or pharmacologic disruption of LTbR signaling in MSCs restores lymphopoiesis but not erythropoiesis, reduces leukemic cell growth, and significantly extends the survival of transplant recipients. Similarly, CXCR4 blocking also prevents leukemia-induced IL7 downregulation, and inhibits leukemia growth. These studies demonstrate that acute leukemias exploit physiological mechanisms governing hematopoietic output as a strategy for gaining competitive advantage.

Data availability

Accession number to RNA expression data were deposited in NCBI (GSE221243)

The following data sets were generated

Article and author information

Author details

  1. Xing Feng

    Department of Immunobiology, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  2. Ruifeng Sun

    Department of Immunobiology, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  3. Moonyoung Lee

    Department of Biomedical Sciences, Korea University, Seoul, Republic of Korea
    Competing interests
    No competing interests declared.
  4. Xinyue Chen

    Department of Cell Biology, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8288-7685
  5. Shangqin Guo

    Department of Cell Biology, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1157-0423
  6. Huimin Geng

    Department of Laboratory Medicine, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  7. Marcus Müschen

    Department of Immunobiology, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  8. Jungmin Choi

    Department of Biomedical Sciences, Korea University, Seoul, Republic of Korea
    For correspondence
    jungminchoi@korea.ac.kr
    Competing interests
    Jungmin Choi, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8614-0973
  9. Joao Pedro Pereira

    Department of Immunobiology, Yale University, New Haven, United States
    For correspondence
    joao.pereira@yale.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5694-4938

Funding

NIH Office of the Director (R01AI113040)

  • Joao Pedro Pereira

NIH Office of the Director (R21AI133060)

  • Joao Pedro Pereira

NIH Office of the Director (R35CA197628)

  • Marcus Müschen

NIH Office of the Director (R01AI164692)

  • Marcus Müschen

NIH Office of the Director (R21AI146648)

  • Marcus Müschen

NIH Office of the Director (T32 DK007356)

  • Xing Feng

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All mice were maintained under specific pathogen-free conditions at the Yale Animal Resources Center and were used according to the protocol approved by the Yale University Institutional Animal Care and Use Committee. (2022-11377).

Copyright

© 2023, Feng et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 874
    views
  • 153
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Xing Feng
  2. Ruifeng Sun
  3. Moonyoung Lee
  4. Xinyue Chen
  5. Shangqin Guo
  6. Huimin Geng
  7. Marcus Müschen
  8. Jungmin Choi
  9. Joao Pedro Pereira
(2023)
Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin-beta receptor signaling.
eLife 12:e83533.
https://doi.org/10.7554/eLife.83533

Share this article

https://doi.org/10.7554/eLife.83533

Further reading

    1. Immunology and Inflammation
    2. Medicine
    Ole Bæk, Tik Muk ... Duc Ninh Nguyen
    Research Article

    Preterm infants are susceptible to neonatal sepsis, a syndrome of pro-inflammatory activity, organ damage, and altered metabolism following infection. Given the unique metabolic challenges and poor glucose regulatory capacity of preterm infants, their glucose intake during infection may have a high impact on the degree of metabolism dysregulation and organ damage. Using a preterm pig model of neonatal sepsis, we previously showed that a drastic restriction in glucose supply during infection protects against sepsis via suppression of glycolysis-induced inflammation, but results in severe hypoglycemia. Now we explored clinically relevant options for reducing glucose intake to decrease sepsis risk, without causing hypoglycemia and further explore the involvement of the liver in these protective effects. We found that a reduced glucose regime during infection increased survival via reduced pro-inflammatory response, while maintaining normoglycemia. Mechanistically, this intervention enhanced hepatic oxidative phosphorylation and possibly gluconeogenesis, and dampened both circulating and hepatic inflammation. However, switching from a high to a reduced glucose supply after the debut of clinical symptoms did not prevent sepsis, suggesting metabolic conditions at the start of infection are key in driving the outcome. Finally, an early therapy with purified human inter-alpha inhibitor protein, a liver-derived anti-inflammatory protein, partially reversed the effects of low parenteral glucose provision, likely by inhibiting neutrophil functions that mediate pathogen clearance. Our findings suggest a clinically relevant regime of reduced glucose supply for infected preterm infants could prevent or delay the development of sepsis in vulnerable neonates.

    1. Immunology and Inflammation
    Alexander J Knights, Easton C Farrell ... Tristan Maerz
    Research Article

    Synovium is home to immune and stromal cell types that orchestrate inflammation following a joint injury; in particular, macrophages are central protagonists in this process. We sought to define the cellular and temporal dynamics of the synovial immune niche in a mouse model of post-traumatic osteoarthritis (PTOA), and to identify stromal-immune crosstalk mechanisms that coordinate macrophage function and phenotype. We induced PTOA in mice using a non-invasive tibial compression model of anterior cruciate ligament rupture (ACLR). Single-cell RNA-sequencing and flow cytometry were used to assess immune cell populations in healthy (Sham) and injured (7 and 28 days post-ACLR) synovium. Characterization of synovial macrophage polarization states was performed, alongside computational modeling of macrophage differentiation, as well as implicated transcriptional regulators and stromal-immune communication axes. Immune cell types are broadly represented in healthy synovium, but experience drastic expansion and speciation in PTOA, most notably in the macrophage portion. We identified several polarization states of macrophages in synovium following joint injury, underpinned by distinct transcriptomic signatures, and regulated in part by stromal-derived macrophage colony-stimulating factor signaling. The transcription factors Pu.1, Cebpα, Cebpβ, and Jun were predicted to control differentiation of systemically derived monocytes into pro-inflammatory synovial macrophages. In summary, we defined different synovial macrophage subpopulations present in healthy and injured mouse synovium. Nuanced characterization of the distinct functions, origins, and disease kinetics of macrophage subtypes in PTOA will be critical for targeting these highly versatile cells for therapeutic purposes.